GlassScriptPhysician profile
Susan Joseph
NPI 1487860060
$64,743.16
in general payments reported to CMS, 2019-2025
25 companies · $6,824 in 2025
The $6,824 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $928 · 2021: $13K · 2022: $4,593 · 2023: $461 · 2024: $1,730 · 2025: $6,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,407 · Travel and Lodging: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,407.00 |
| Travel and Lodging | $2,607.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39,279.08 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Ancora Heart, INC. | $7,871.67 | 2019-2022 | |
| Medtronic Vascular, INC. | $4,890.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $3,401.96 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $2,527.09 | 2024-2025 | Optimizer |
| Medtronic, INC. | $2,100.00 | 2021 | |
| Cvrx, INC. | $1,503.80 | 2023-2025 | Barostim Neo System |
| Abiomed | $786.64 | 2022-2025 | Impella |
| Amgen INC. | $751.52 | 2019 | |
| Novo Nordisk INC | $375.17 | 2024-2025 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.85 | 2022-2025 | Lifevest |
| Atricure, INC. | $155.51 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $120.45 | 2020 | |
| Pfizer INC. | $101.40 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $100.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.18 | 2019-2025 | Jardiance |
| Zoll Respicardia, INC. | $77.41 | 2025 | Remede System |
| Actelion Pharmaceuticals US, INC. | $45.99 | 2025 | Uptravi, Opsynvi |
| Alnylam Pharmaceuticals INC. | $43.94 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $35.78 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $33.24 | 2025 | Eliquis |
| Daiichi Sankyo INC. | $26.77 | 2025 | Injectafer |
| Heartflow, INC. | $23.40 | 2025 | |
| Allergan, INC. | $22.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.